AI assistant
Tvardi Therapeutics, Inc. — Director's Dealing 2021
Apr 23, 2021
9999_dirs_2021-04-23_14fb681f-041b-4b6a-9cd8-9b02a1eb9090.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cara Therapeutics, Inc. (CARA)
CIK: 0001346830
Period of Report: 2021-04-21
Reporting Person: Goncalves Joana (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-21 | Common Stock | S | 3000 | $27.63 | Disposed | 43610 | Direct |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019 and amended on August 19, 2020.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.41 - $28.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.